Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | IDUA | P35475 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8169843 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL18302566 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL346996 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL346997 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL18682065 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL25387433 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL9332338 | 0.98 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| SCHEMBL5042482 | 0.98 | HCRTR1 (0.35) | HCRTR1HCRTR2TMEM97SIGMAR1CA2 | |
| Water SCHEMBL10648449 | 0.96 | HCRTR1 (0.34) | HCRTR1HCRTR2TMEM97SIGMAR1 | |
| SCHEMBL14793014 | 0.86 | HCRTR1 (0.33) | HCRTR1HCRTR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-04-28 | — | — | US | claimed |
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-12-27 | — | — | US | claimed |
| EP-3313847-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN Laboratories Private Limited (IN) | 2018-05-02 | — | — | EP | claimed |
| WO-2016207907-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-12-29 | — | — | WO | claimed |
| US-7361775-B2 | Process for the preparation of (S)-glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2008-04-22 | — | — | US | claimed |
| EP-1673364-B1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS BV (NL) | 2007-08-22 | — | — | EP | claimed |
| US-20070073068-A1 | Process for the preparation of (s)-glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2007-03-29 | — | — | US | claimed |
| CN-1863787-A | Process for the preparation of -glyceraldehyde acetonide | DSM IP ASSETS BV (NL) | 2006-11-15 | — | — | CN | claimed |
| EP-1673364-A1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP Assets B.V. (NL) | 2006-06-28 | — | — | EP | claimed |
| WO-2005037819-A1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS B.V. (NL) | 2005-04-28 | — | — | WO | claimed |
| EP-0111326-B1 | PROCESS FOR THE MANUFACTURE OF CHIRAL AZETIDINONES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-01-11 | — | — | EP | claimed |
| EP-0143973-B1 | METHOD OF PRODUCING (S)-GLYCERALDEHYDE ACETONIDE | Takeda Chemical Industries, Ltd. (JP) | 1988-03-02 | — | — | EP | claimed |
| CN-85101931-A | The preparation method of symmetry (S)-Glycerose acetonide | — | 1987-01-24 | — | — | CN | claimed |
| US-4567282-A | Method of producing (S)-glyceraldehyde acetonide | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-01-28 | — | — | US | claimed |
| EP-0143973-A1 | Method of producing (S)-Glyceraldehyde Acetonide | Takeda Chemical Industries, Ltd. (JP) | 1985-06-12 | — | — | EP | claimed |
| JP-60094977-A | — | — | None | — | — | JP | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-4567282-A | Method of producing (S)-glyceraldehyde acetonide | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-01-28 | — | — | US | disclosed |
| EP-0143973-A1 | Method of producing (S)-Glyceraldehyde Acetonide | Takeda Chemical Industries, Ltd. (JP) | 1985-06-12 | — | — | EP | disclosed |
| JP-S6094977-A | PRODUCTION OF (S)-GLYCERALDEHYDE ACETONIDE | TAKEDA CHEM IND LTD | 1985-05-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | FFAR1, CYP2S1, CYP1B1 | HCRTR1 1258/4885HCRTR2 2134/4885TMEM97 2110/4885 |
| US-20070073068-A1 | Process for the preparation of (s)-glyceraldehyde acetonide | AKR1C3, AK1, GAPDH | HCRTR1 1773/4885HCRTR2 2660/4885TMEM97 4333/4885 |
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | FFAR1, CYP2S1, FFAR3 | HCRTR1 1277/4885HCRTR2 2123/4885TMEM97 2137/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | HCRTR1 4581/4885HCRTR2 4650/4885TMEM97 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.